Armistice Capital and Steven Boyd Disclose 185K-Share Position in AEMD

Rhea-AI Filing Summary

Armistice Capital, LLC and Steven Boyd report beneficial ownership of 185,000 shares of Aethlon Medical Inc. Together they hold 7.16% of the outstanding common stock, based on 2,585,316 shares outstanding as of June 24, 2025. Armistice Capital is the investment manager of the Armistice Capital Master Fund Ltd., the direct holder of the shares, and exercises shared voting and dispositive power over the securities. Mr. Boyd, as managing member, is reported to share those voting and disposition rights. The Master Fund disclaims direct beneficial ownership due to its investment management agreement.

Positive

• Material ownership disclosed: Reporting Persons clearly state they beneficially own 185,000 shares (7.16% of class).
• Transparency on control: Filing explains Armistice Capital's investment manager role and Mr. Boyd's managing member status.

Negative

• None.

Insights

Financial Analyst

TL;DR: A 7.16% stake is material but consistent with an investment manager filing; monitor for future schedule changes.

Armistice Capital and Steven Boyd disclose shared voting and dispositive power over 185,000 AEMD shares, representing 7.16% of the class. This disclosure clarifies control relationships: the Master Fund holds the shares while Armistice, via an Investment Management Agreement, directs voting and disposition. The filing provides transparency on ownership concentration without indicating any change to control. For investors, the key takeaway is identification of a significant shareholder and the governance link through the investment manager.

Corporate Governance Expert

TL;DR: Disclosure aligns with governance norms; beneficial ownership is attributed to the manager and its principal.

The Schedule 13G/A attributes beneficial ownership to Armistice Capital and Steven Boyd while noting the Master Fund's disclaimer due to the investment management arrangement. The filing properly reports shared voting and dispositive power and quantifies the stake relative to outstanding shares. This is a routine but material governance disclosure that informs shareholders about an entity with significant influence over voting outcomes, though it does not assert a change in control intent.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

AETHLON MEDICAL INC

(Name of Issuer)

COMMON STOCK, $0.001 PAR VALUE

(Title of Class of Securities)

02008G201

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 02008G201

1

Names of Reporting Persons

Armistice Capital, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 185,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 185,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

185,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.16 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP No. 02008G201

1

Names of Reporting Persons

Steven Boyd

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 185,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 185,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

185,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.16 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: AETHLON MEDICAL INC
(b)	Address of issuer's principal executive offices: 11555 SORRENTO VALLEY ROAD, SUITE 203, SAN DIEGO, CA, 92121
Item 2.
(a)	Name of person filing: Armistice Capital, LLC Steven Boyd Collectively, the "Reporting Persons"
(b)	Address or principal business office or, if none, residence: Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America Steven Boyd c/o Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America
(c)	Citizenship: Armistice Capital, LLC - Delaware; Steven Boyd - United States of America
(d)	Title of class of securities: COMMON STOCK, $0.001 PAR VALUE
(e)	CUSIP No.: 02008G201
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 185,000
(b)	Percent of class: 7.16%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 185,000
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 185,000 The percentage of Shares reported to be beneficially owned by the Reporting Persons are based on 2,585,316 Shares outstanding as of June 24, 2025, as reported on the Issuer's Form 10-K filed with the Securities and Exchange Commission on June 26, 2025. Armistice Capital, LLC ("Armistice Capital") is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Armistice Capital, LLC

Signature:	/s/ Steven Boyd
Name/Title:	Steven Boyd - Managing Member
Date:	08/14/2025

Steven Boyd

Signature:	/s/ Steven Boyd
Name/Title:	Steven Boyd
Date:	08/14/2025

Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: August 14, 2025 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

FAQ

How many AEMD shares does Armistice Capital report owning?

The filing states the Reporting Persons beneficially own 185,000 shares of Aethlon Medical Inc.

What percentage of AEMD does the 185,000 shares represent?

The reported position represents 7.16% of Aethlon Medical's outstanding common stock based on 2,585,316 shares.

Who exercises voting and disposition power over these AEMD shares?

Armistice Capital, as investment manager of the Master Fund, exercises shared voting and dispositive power; Steven Boyd, as managing member, is reported to share that power.

Does the Master Fund claim beneficial ownership of the AEMD shares?

No. The Master Fund specifically disclaims beneficial ownership due to its inability to vote or dispose of the securities under the Investment Management Agreement.

What type of filing is this for AEMD?

This document is a Schedule 13G/A reporting ownership and related disclosures for Aethlon Medical Inc.